Valuation: Alcon

Market Cap 34.43B 30.1B 27.83B 25.54B 48.34B 3,318B 49.18B 332B 130B 1,620B 129B 126B 5,593B P/E 2026 *
31.4x
P/E 2027 * 24.7x
Enterprise Value 37.03B 32.36B 29.93B 27.47B 51.98B 3,568B 52.89B 357B 140B 1,742B 139B 136B 6,015B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 3.04x
Free-Float
97.36%
Yield 2026 *
0.51%
Yield 2027 * 0.59%
Manager TitleAgeSince
Chief Executive Officer 60 2018-06-30
Director of Finance/CFO 58 2019-04-07
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 2018-06-30
Director/Board Member 63 2019-01-31
Change 5-day change 1-year change 3-year change Capi.($)
+18.17%0.00% - - 33.48B
+0.77%-1.25%-30.22%-3.19% 88.44B
+2.97%+2.55%+0.18%-26.06% 13.77B
-1.97%-0.54% - - 9.84B
+4.80%-5.50%-30.15%+503.95% 1.81B
+2.69%+7.50%-26.06%-64.05% 1.48B
-1.51%-4.13%+22.28%-2.84% 871M
+2.94%+6.35%-34.05%-22.52% 868M
+2.68%+2.01%+49.61%-29.79% 769M
-0.56%+2.04% - - 689M
Average +1.28%-0.59%-6.92%+50.79% 13.17B
Weighted average by Cap. +0.69%-0.99%-25.32%+1.21%

Financials

2026 *2027 *
Net sales 11.14B 9.74B 9B 8.26B 15.64B 1,073B 15.91B 107B 42.18B 524B 41.83B 40.91B 1,809B 11.82B 10.33B 9.55B 8.76B 16.59B 1,139B 16.88B 114B 44.75B 556B 44.37B 43.4B 1,919B
Net income 1.11B 973M 900M 826M 1.56B 107B 1.59B 10.73B 4.22B 52.39B 4.18B 4.09B 181B 1.38B 1.21B 1.11B 1.02B 1.94B 133B 1.97B 13.29B 5.22B 64.88B 5.18B 5.06B 224B
Net Debt 2.6B 2.27B 2.1B 1.93B 3.64B 250B 3.71B 25.02B 9.83B 122B 9.75B 9.53B 422B 1.54B 1.35B 1.25B 1.14B 2.16B 148B 2.2B 14.86B 5.84B 72.51B 5.79B 5.66B 250B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA